Moreover, comparison on the expressions of seven immune checkpoint genes indicated that the expression of four immune checkpoint genes (PDCD1, HAVCR2, TIGIT, and LAG3) was higher in high-risk group (Fig. 6C), showing that high-risk COAD patients had strong immune escape ability and limited benefits from immune checkpoint inhibitors. This evidence concerns the gene LAG3 and colon adenocarcinoma.